Advertisement
Screener

Allogene Therapeutics, Inc. (ALLO) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Allogene Therapeutics, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Allogene Therapeutics, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $149.25M went out.
  • Fiscal year ended 2025-12-31: from investing, $95.56M came in.
  • Fiscal year ended 2025-12-31: from financing, $30.16M came in.
  • Fiscal year ended 2025-12-31: change in cash, $23.53M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingNew shares soldNot split outChange in cash
2025-12-31-$149.25M$95.56M$895.00K$29.26M*-$23.53M
2024-12-31-$200.30M$75.69M$1.53M$115.14M*-$7.94M
2023-12-31-$237.73M$163.29M$91.11M$4.58M*$21.25M
2022-12-31-$220.52M$106.16M$0.00$2.95M*-$111.41M
2021-12-31-$184.81M$163.66M$0.00$11.96M*-$9.19M
2020-12-31-$115.09M-$505.12M$595.73M$37.86M*$13.38M
2019-12-31-$137.35M$164.08M$0.00$58.96M*$85.69M
2018-12-31-$44.65M-$632.80M$343.69M$427.49M*$93.73M

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew shares soldNot split outChange in cash
2026-06-30-$32.00M*-$147.56M*$0.00*$187.87M*
2026-03-31-$12.91M-$29.59M$450.00K$20.67M*-$21.38M
2025-12-31-$27.60M*$33.61M*$0.00*$7.86M*
2025-09-30-$29.69M*$11.94M*$257.00K*$2.98M*
2025-06-30-$39.03M*$43.84M*$0.00*$5.07M*
2025-03-31-$52.93M$6.18M$10.00M$3.99M*-$32.76M
2024-12-31-$36.70M*$54.93M*$0.00*$5.74M*
2024-09-30-$44.12M*-$75.99M*$679.00K*
2024-06-30-$63.59M*$74.61M*$0.00*$108.60M*
2024-03-31-$55.90M$22.13M$0.00$1.65M*-$32.12M
2023-12-31-$53.71M*$67.46M*$0.00*
2023-09-30-$55.53M*-$34.27M*$3.19M*$1.09M*
2023-06-30-$61.86M*$17.16M*$0.00*$89.52M*
2023-03-31-$66.64M$112.94M$1.73M$48.03M
2022-12-31-$62.10M*$49.60M*$0.00*
2022-09-30-$47.66M*$24.91M*$0.00*$1.07M*
2022-06-30-$42.53M*$54.03M*-$1.00K*
2022-03-31-$68.24M-$22.38M$1.53M-$88.80M
2021-12-31-$45.44M*$29.25M*$0.00*
2021-09-30-$48.88M*$13.01M*$1.63M*$750.00K*
2021-06-30-$41.17M*$24.59M*$0.00*$3.21M*
2021-03-31-$49.33M$96.80M$1.98M$4.06M*$53.51M
2020-12-31-$9.97M*$22.21M*-$1.00K*$12.98M*
2020-09-30-$37.59M*-$83.36M*$1.41M*$2.45M*
2020-06-30-$26.72M*-$428.97M*$0.00*$600.17M*
2020-03-31-$40.81M-$15.01M$14.85M$1.74M*-$39.23M
2019-12-31-$50.27M*$7.93M*$0.00*$56.47M*
2019-09-30-$31.93M*$78.78M*$1.10M*
2019-06-30-$24.89M*$44.49M*$0.00*
2019-03-31-$30.26M$32.89M$0.00$684.00K*$3.32M
2018-12-31-$21.48M*-$313.39M*$0.00*$344.52M*
2018-09-30-$17.13M*-$316.78M*$0.00*$274.06M*
2018-06-30-$6.05M*-$2.63M*$0.00*$152.60M*
2018-03-31$5.00K$0.00$0.00$5.00K

Similar stocks

Stock NameCountryMarket CapPE Ratio
Prime Medicine, Inc. (PRME)United States$0.557B-3.54
Aura Biosciences, Inc. (AURA)United States$0.639B-5.61
Autolus Therapeutics plc (AUTL)$0.506B-1.52
Entera Bio Ltd. (ENTX)$0.485B
REGENXBIO Inc. (RGNX)United States$0.477B-3.30
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10